$AMPG Q2 Revenue Rose 55% to $1.0M Driven by Expanding Sales Efforts and Growing Demand for its Low Noise Signal Amplifiers That Enhance Satellite, Telecom (5G) and Other Communications; Quarter-End Cash & Securities of $28.7M

BOHEMIA, NY, Aug. 16, 2021 — AmpliTech Group, Inc. (Nasdaq: AMPG), a designer, developer and manufacturer of state-of-the-art communications components for satellite communications, space, telecom (5G/6G) and defense markets, today reported financial results for its second quarter and first six months of 2021 (Q2’21 and 6M’21) and reviewed its growth outlook.

AmpliTech is a world leading developer of Low Noise Amplifier (LNA) components which increase the power of a radio signal while eliminating the distortion or “noise” that can degrade or destroy digital signals. AmpliTech believes its LNA technology can play a vital role enabling substantial performance and bandwidth improvements in satellite communications and in achieving gigabit data transmission speeds in next generation 5G networks.

Highlights

• Q2’21 revenue rose 55% to $1,024,410 vs. $660,699 in Q2’20 and increased 117% vs. Q1’21.
• AmpliTech’s order backlog as of August 16 ^th was $2.45M in contractual hardware and engineering services anticipated for delivery over the next three-to-six months, versus $2.4M at the close of Q1’21.
• Secured Follow-On LNA Order from Fortune 500 global defense and aerospace company with expected shipment in Q3’21.
• Secured $0.5M in orders in July for custom LNAs to be used in ground stations for geosynchronous equatorial orbit (GEO), low earth orbit (LEO) and medium earth orbit (MEO) satellite systems. Shipments are also anticipated in Q3’21.

First Six Months Highlights

• Completed a financial recapitalization and Nasdaq up-listing in the first half of 2021, yielding working capital of $29.8M as of June 30th. The capital is supporting expanded product development, sales and marketing and infrastructure investments while also providing the financial strength required to engage with global customer prospects previously outside AmpliTech’s reach.
• Paid off $1M in debt, secured $0.2M in SBA loan forgiveness, purchased $0.4M in scientific equipment to enhance product development and testing and made a strategic investment in its secure LNA chip development joint venture partner SN2N.
• Achieved design wins for AmpliTech’s LNA product suite which reaffirm its industry leading performance, extreme durability, and low power (and heat) dissipation. AMPG LNA components power satellite constellations and cellular/IoT devices, and its super-cooled cryogenic LNA components deliver signal amplification performance required for quantum computing systems and deep space research.
• Began development, product testing and design integration for LNA chipsets with hardware encryption to power un-hackable 5G networks that deliver increased data flow and security to enable expanded content and data distribution as well as IoT device adoption
• Built out expanded sales and marketing team and structure targeting major OEMs as well as system integrators to substantially expand the Company’s addressable market.
• Established an on-site testing laboratory to expedite new product development while reducing variable R&D costs and increasing quality control.

Fawad Maqbool, President, CTO, and CEO, said, “Our Q2 results reflect initial benefits of our significantly enhanced financial position and the gradual return of customer prospects to more normal planning and procurement activity for projects where our low noise amplifier solutions can deliver game-changing performance and ROI. Importantly, our financial recapitalization is allowing AmpliTech to engage for the first time with a range of very large customer prospects that were previously out of our reach.

“We are making strategic investments in product development, sales & marketing and personnel and infrastructure to better position AmpliTech for hyper-growth opportunities we see across several markets, including satellite communications, the build out of true 5G infrastructure, quantum computing and space exploration.

“To address this very large and diversified base of long-term opportunities, we are transferring our decades of experience and industry-leading signal amplification technology into semiconductor chip-based solutions targeted for launch mid-next year. We have had excellent customer interest in these next-generation LNA solutions which will offer performance enhancements, built in hardware security, a far smaller footprint and a lower price point – for a very compelling ROI for customers.

“The next several years are expected to see unprecedented growth in the demand for wireless connectivity to power the proliferation of devices and rapid expansion in bandwidth requirements from cloud computing, content streaming, Internet of Things (IoT) applications, autonomous vehicles, quantum computing and space exploration.

Outlook
“AmpliTech is positioning itself to be a key infrastructure provider to support satellite, 5G and other radio frequency communications infrastructure that will be scaling rapidly to address these growing needs. Given our substantially strengthened financial, product and industry position and the very favorable industry backdrop, we anticipate significant growth potential for our Company in the coming years.

“We expect our industry-leading product performance, new product offerings and growing end-market demand for cost effective digital bandwidth will drive substantial growth for AmpliTech for years to come. We are also working to identify potential tuck-in acquisitions of complementary businesses that can expand our customer capabilities, footprint and value-add.

“Our business development efforts are proceeding well, enabling a growing base of new customer dialogues that are progressing to custom designs as well as initial product testing. We anticipate generally improving market conditions over the balance of 2021, though with some potential for project delays related to the COVID-19 pandemic and its impact on customer activity, along with related supply chain challenges. Throughout, we will remain sharply focused on balancing our growth investments with our revenue ramp and margin profile in order to drive the business to positive cash flow and profitability.”

Q2’21 Results
Q2’21 revenue rose 55% to $1,024,410 vs. $660,699 in Q2’20 and increased 117% vs. Q1’21, reflecting the Company’s expanded sales efforts along with a return to more normal business conditions versus disruptions in customer activity related to the COVID-19 pandemic. AmpliTech was successful in rebuilding its order backlog during a strong period of product deliveries, yielding a current backlog of $2.45M which provides a solid outlook for the balance of the year.

Gross profit rose 52.5% to $344,623 in Q2’21 compared to $225,988 in Q2’20, reflecting the increase in revenue and a relatively stable gross margin of 33.6% in Q2’21 compared to 34% in Q2’20.

Selling, general and administrative expense increased to $1,043,550 in Q2’21 from $442,457 in Q2’20 principally due to investments in expanded sales, marketing, R&D, management, administrative and public-company activities and personnel intended to support long term growth. Q2’21 also included approximately $116,000 in expenses related to the Company’s common stock offering in the period, offset by a Q2’21 $232,200 gain on the extinguishment of debt reflecting forgiveness of the Company’s PPP loan.

AmpliTech reported a Q2’21 net loss of ($472,695), or ($0.05) per share, compared to a net loss of ($243,268), or ($0.10) per share, in Q2’20. Weighted average shares outstanding increased to 8,863,517 in Q2’21, reflecting shares issued in the Company’s common stock offerings in the first half of 2021, compared to 2,476,816 shares outstanding in Q2’20. As of August 10, 2021, AmpliTech had 9,343,671 shares of common stock outstanding.

Balance Sheet
AmpliTech had working capital of $29.8M at the close of Q2’21, including cash, cash equivalents and marketable securities totaling $28.7M, reflecting proceeds from the Company’s public offerings in February and April 2021.

About AmpliTech Group, Inc. ( www.AmpliTechinc.com )

AmpliTech Group, Inc. designs, develops, and manufactures state-of-the-art radio frequency (RF) components for global satellite communications, telecom (5G & IoT), space, defense, and quantum computing markets as well as systems and component design consulting services. AmpliTech has a 13+ year track record of developing high performance, custom solutions to meet the unique needs of some of the largest companies in the global industries we serve. We are proud of the unique skills, experience and dedication of our focused team which enables us to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s ability to execute its business plan as anticipated; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

Company
Twitter: AmpliTechAMPG
Instagram: AmpliTechAMPG
Facebook: AmpliTechInc

Investor Relations
Twitter: AmpliTechIR
StockTwits: AMPG_IR

Investor Contact

David Collins
Catalyst IR
AMPG@catalyst-ir.com or 212-924-9800

$WTER Alkaline88(R) Adds Flagship Product for Strategic Hospitality Channel Expansion

$VVOS Reports Second Quarter 2021 Financial Results and Operational Update

Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021

Management to Host Conference Call Today at 5:00 pm ET

HIGHLANDS RANCH, Colo., Aug. 12, 2021 — Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2021.

Financial and Operating Highlights:

• Revenue increased 37.5% to $4.5 million for the second quarter of 2021 and was $7.9 million for the six months ended June 30, 2021, compared to $3.3 million and $6.5 million for the three and six months ended June 30, 2020, respectively;
• Revenue increased 30% in the second quarter of 2021 over revenue from the first quarter of 2021;
• Gross profit was $3.6 million for the second quarter of 2021 and $6.3 million for the six months ended June 30, 2021, compared to gross profit of $2.7 million and $5.1 million for the comparable periods in 2020, respectively;
• Gross margin was 81% for the second quarter of 2021, compared to 83% for the second quarter of 2020, and remained consistent at 79% for the first six months of both 2021 and 2020, reflecting high margin service revenues;
• General and administrative expenses were $6.1 million for the second quarter of 2021 and $11.2 million for the six months ended June 30, 2021, compared to $3.5 million and $7.7 million for the three and six months ended June 30, 2020, respectively, reflecting Vivos’ investment in new personnel as well as public company costs and other general and administrative expenses;
• Net loss was $4.0 million and $7.4 million for the three and six months ended June 30, 2021, compared to $1.4 million and $4.0 million for the comparable periods in 2020, respectively;
• Cash and cash equivalents were $34.2 million at June 30, 2021;
• During the second quarter of 2021, Vivos surpassed 19,000 total patients treated with the Vivos System;
• In April 2021, Vivos appointed Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical Director of Clinical Education. The Company also retained the services of Amy Osmond Cook, PhD and her team at Osmond Marketing to lead the Company’s marketing and sales efforts going forward;
• In May 2021, the Company completed an underwritten follow-on offering of 4,600,000 shares of its common stock and the exercise in full of the underwriters’ option to purchase additional shares, for net proceeds of $25.4 million;
• Also in May, the Company’s Founder and Chief Medical Officer, Dr. G. Dave Singh, DMD, Ph.D., DDSc., released a new book titled Pneumopedics and Craniofacial Epigenetics to help doctors and dentists better understand how to address underlying craniofacial conditions that affect a patient’s overall airway, breathing and sleep health;
• Subsequent to quarter end, in July, the Company unveiled new data from an independent patient survey related to its proprietary Vivos treatment, showing nearly 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA;
• Also in July, the Company announced results from a national study commissioned by the Company to assess patients’ airway function and OSA symptoms after undergoing the Vivos treatment. In the study, 28 percent of the 74 adult patients treated with the Company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms; and
• Later in July, Vivos announced the opening of The Vivos Institute training center in Denver, Colorado. This 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other healthcare providers from around the world in a live and hands-on setting.

“There are a number of key positive takeaways from our second quarter results,” said R. Kirk Huntsman, Vivos’ Chairman and CEO. “First, we achieved strong revenue results ahead of our internal forecasts and analysts’ estimates, although the year over year comparisons are somewhat augmented due to the impact of COVID last year.”

“Second, we have continued to focus on strategic sales and marketing initiatives, designed to introduce more healthcare and dental professionals to the benefits of the Vivos System. Chief among these initiatives was the launch of our VivoScore sleep apnea test, which our VIPs have utilized nearly 2,000 times with patients since launch. In a sample survey of nearly 60 VIP practices that converted over to VivoScore as their primary home sleep apnea test, the total number of VivoScore sleep tests performed was up over 300% versus prior period testing with alternative sleep apnea test technologies. This remarkable surge in sleep apnea testing means more dentists and sleep physicians are having dialogues with more candidates for Vivos System. It remains to be seen just how many of these patients will eventually start treatment with the Vivos System, but we are closely monitoring this process and working with dentists to help close cases where appropriate. Our business model is centered on treating sleep apnea via the dental community, and we believe more dentists talking with their patients about sleep apnea, and testing patients for sleep apnea, will lead to more dentists signing up as VIPs and more case starts with the Vivos System. Our second quarter results reflect the impact of these measures when compared to first quarter, with growing enrollments by new VIP dentists and sequential increases of 25% and 34% for products and services revenue, respectively. These strong results demonstrate the continuing recognition and adoption of the Vivos System by the dental community with growing awareness and support from medical doctors and other healthcare providers.”

“Third, in addition to our core business of enrolling new VIPs and increasing sales of appliances, we have begun to see revenue from other sources we have implemented, including from our recently launched MyoCorrect orofacial myofunctional therapy service and the beginnings of management fee revenue from our Medical Integration Division as well as some revenue from VivoScore (which we view principally as a marketing tool). While we just introduced these new revenue lines, demand has already surpassed our original expectations. Based on this, we believe these areas represent meaningful upside to our revenue potential as they build further momentum throughout the second half of this year and beyond. What’s more, we are constantly looking to develop new potential revenue sources as the good word spreads about Vivos and the Vivos System (as evidenced by our recently released patient data).”

“Fourth, we have recently begun an active outreach to the DSO industry. DSOs, or Dental Support Organizations, own and operate thousands of dental practices throughout the U.S. and Canada. Very few DSOs have successfully implemented a dental sleep management program, although several have tried. Our management team’s extensive DSO experience gives us a huge advantage in penetrating this market. Not only do we personally know the key players, but we have also specifically designed our model to seamlessly integrate and thrive within the corporate DSO environment. The initial response from the DSO community has been extremely positive, and we are working very closely with a number of these companies to initiate pilot tests within certain target markets.”

“In sum, we believe that the continuing formulation and implementation of our growth plans, supported by our augmented balance sheet after our follow-on public offering during the second quarter, leave us well placed to continue our growth during the balance of 2021 and into the following year. One cautionary note to our realization of these objectives would be the impact and disruption in dental patient access or uncertainty caused by a resurgence of COVID, which we are monitoring daily.”

Further information on Vivos’ financial results is included on the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Vivos’ financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2021, which will be filed with the Securities and Exchange Commission (“SEC”). The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivoslife.com/investor-relations/ .

Business Updates

In April 2021, Vivos appointed Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical Director of Clinical Education. Dr. Guarneri is widely acclaimed as a leading Integrative Cardiologist in America. She is Board-certified in Cardiovascular Disease, Internal Medicine, Nuclear Cardiology, and Integrative Holistic Medicine. Dr. Guarneri is a Founder and President of The Academy of Integrative Health and Medicine. She serves on the Founding Board of the American Board Physician Specialties in Integrative Medicine and is a Clinical Associate Professor at the University of California, San Diego. In addition to her responsibilities related to Vivos’ first Pneusomnia Center, Dr. Guarneri duties for the Company include the promotion and expansion of the Company’s Medical Integration Division.

On May 11, 2021, Vivos closed an underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters’ option to purchase additional shares of common stock, at a public offering price of $6.00 per share. The aggregate gross proceeds to Vivos from the public offering was $27.6 million prior to deducting underwriting discounts, commissions and other estimated offering expenses.

In July, the Company unveiled new data from an independent patient survey related to its proprietary Vivos treatment, showing nearly 97% of patients surveyed said that they had achieved their desired outcome from Vivos System treatment for their OSA. Other key findings included:

• Over half (63%) of patients surveyed said that they rely on the advice of their dentist to find a lasting solution that addresses the root cause of their OSA; and
• Nearly one-third (29%) of patients surveyed said that they searched for non-surgical alternatives to current standards of care for treating OSA.

Also in July, Vivos announced results from a national study commissioned by Vivos to assess patients’ airway function and OSA symptoms after undergoing the Vivos treatment. In the study, 28% of 74 adult patients treated with the Company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, which is defined as patients having an Apnea Hypopnea Index (AHI) score of less than five post-treatment. This real world patient data was gathered from multiple sites and has been submitted to the U.S. Food and Drug Administration to be used as part of the Company’s process for obtaining 510k clearance for the DNA appliance to treat mild-to-moderate OSA.

On July 29, 2021, the Company announced the opening of The Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other healthcare providers from around the world in a live and hands-on setting. The Institute’s emphasis will be on educating healthcare providers about OSA and Vivos’ treatments for OSA within their practice areas, along with training on Vivos’ related practice management tools for dentists.

Conference Call

The Company will conduct a conference call today, August 12, 2021 at 5:00 p.m. (Eastern Time) to review the second quarter results as well as provide an overview of the Company’s recent milestones and growth strategy.

To access the conference call, please dial (888) 204-4368, or for international callers, (720) 543-0214. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 3460553. The replay will be available until August 26, 2021.

A live webcast of the conference call can be accessed on Vivos’ website at https://vivoslife.com/investor-relations/ . An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 dentists. Combining technologies and protocols that alter the size, shape, and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

For more information, visit www.vivoslife.com .

Cautionary Note Regarding Forward-Looking Statements
This press release, the earnings call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the Company’s future results of operations) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com

Media Relations Contact:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
ckasunich@kcsa.com / jrobles@kcsa.com

VIVOS THERAPEUTICS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets

VIVOS THERAPEUTICS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations (Unaudited)

$TOBAF Names New Board Members

TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) has appointed two new members to its board of directors. The new members — Peter Nguyen and John Martin — will serve as independent directors, effective immediately. Nguyen and Martin will also be serving as audit committee members for the company. TAAT’s board of directors now comprises six directors, four of whom are independent directors as required by leading public stock exchanges. The company’s audit committee members are all independent directors. An alumnus of the University of British Columbia, Nguyen is a chartered professional accountant and currently serves as an officer and director of several publicly traded companies in a variety of industries. He has also garnered more than 10 years of experience in financial reporting and business strategy positions in both public and private entities, where he became expert at providing assurance, corporate financing, tax and business advisory services. Martin has more than three decades of international business experience, primarily in capital markets and fund management. He has held senior positions with Royal Bank of Canada and was head of capital markets at the Bank of Tokyo Mitsubishi in Switzerland. In addition, he established CMI Credit Market Investments, an advisory firm active in distressed debt. “On behalf of the company’s Board of Directors, we are pleased to welcome Nguyen and Martin to the team, who are each bringing to the table unique expertise in public companies,” said TAAT CEO Setti Coscarella said in the press release. “TAAT has made considerable strides in the past year, with public market presences in good standing in Canada, the United States and Germany. Within just nine months of being publicly listed in Canada, TAAT ascended to the OTCQX(R) best market in the United States. Moreover, upon becoming a ‘post-revenue’ company at the end of 2020, TAAT was added to the CSE Composite Index as well as its CSE25(TM) subset, or the 25 largest firms in Composite by market capitalization. We look forward to working with Mr. Nguyen and Mr. Martin as we continue our initiatives to build market share in the $814 billion global tobacco industry.”

To view the full press release, visit https://ibn.fm/S1meW

About TAAT Global Alternatives Inc.

TAAT Global Alternatives has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$SGTM Subsidiary Poised to Deal with Severe Storms, Aftermath

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, and its wholly owned subsidiary National Storm Recovery LLC, are experts at dealing with the aftermath of storms, regardless of their severity. This comes as the National Oceanic and Atmospheric Administration (“NOAA”) Climate Prediction Center is anticipating an above-normal Atlantic hurricane season in the coming months. “The Sustainable Green Team, through National Storm Recovery, offers the kind of expert support and guidance that communities may be looking for in order to prepare for and clean up after severe storms,” reads a recent article. “For the past four decades, National Storm Recovery has provided unparalleled services, ranging from commercial property storm recovery to tree trimming and clean up. National Storm Recovery is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. In addition to superior storm recovery assistance, the company also offers tree removal, stump grinding, tree care, land clearing, and grapple hauling.”

To view the full article, visit https://ibn.fm/MXSai

About Sustainable Green Team Ltd.

Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit https://ibn.fm/ZdiFf.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$RWBYF Announces Scheduled Release of Q2 2021 Results

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is a multistate cannabis operator and house of premium brands. The company has announced the schedule for release of its second-quarter 2021 financial results. According to the update, RWB will be releasing Q2 2021 financial statements, accompanying notes and MD&A after market close on Monday, Aug. 30, 2021.

To view the full press release, visit https://ibn.fm/tru6w

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Florida, Oklahoma, Arizona, and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork

$PBIO New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations

PBI Agrochem Integration into the Sales Channels of Its Planned Asset Acquisition of a Global, Environmentally Responsible Agrochem Company is Expected to Result in a Significant Q3 2021 Impact

SOUTH EASTON, MA / August 12, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced that its newly-formed agrochemicals subsidiary – PBI Agrochem, Inc. – has received initial purchase orders for over $1M of eco-friendly agrochemical products for delivery in 2021. Just three weeks ago, the Company announced the formation of its new agrochemicals division in anticipation of the planned asset acquisition of a global agrochemicals products business focused on organically natural and environmentally responsible products.

PBI’s President and CEO Richard T. Schumacher explained the fast development of early sales: “With integration planning for this acquisition well underway, PBI Agrochem placed an initial order for specialized, proprietary bulk material in July and began establishing U.S. warehousing, processing, and final product packaging facilities. Our objective was to insert PBI Agrochem into the supply chain and sales channels of our acquisition target, in order to capture early sales revenues that we believe could have an immediate, accretive impact upon PBI’s overall operating results. These efforts have resulted in over $1M in 2021 customer orders for eco-friendly and effective agrochemical pest control and growth stimulant products.”

Mr. Schumacher continued: “We anticipate that the delivery and booking for most of these orders will occur during the third quarter 2021. PBI investors who have followed and supported the Company through recent years understand that this new incremental revenue from PBI Agrochem represents a potential doubling (or more) of quarterly revenues, when added to sales of PBI’s existing core products and services. With additional orders expected to arrive over the coming weeks and months, we believe Q4 2021 could substantially exceed the results of Q3 2021. Our new agrochem sales are expected to accelerate PBI’s rapidly improving growth trajectory and should contribute substantially towards our planned transition to profitability by the end of 2022.”

Mr. John B. Hollister, Director of Sales and Marketing at PBI, said: “The market potential in agrochemicals is enormous, driven by the intersection of burgeoning global population growth and accelerating environmental consciousness and priorities. Our positioning in organically natural and ecofriendly product solutions places PBI squarely within the hottest growth generation in this sector. Closing on over $1M of orders in the first month of PBI Agrochem operations is a welcome signpost on the road to major growth and profitability for our agrochem operations. The broad array of eco-friendly products being integrated into PBI will address a diversity of agrochem client needs throughout the year, from fertilizing young plants, to mitigating microbial and larger animal threats, to enhancing the appearance and appeal of finished produce.”

PBI’s Board Chairman Jeffrey N. Peterson commented on the synergies achieved in PBI’s move into agrochemicals: “The creation of many organically natural and effective, environmentally-friendly agrochemical products is typically achieved through utilization of essential oil active ingredients extracted from plants, such as the already popular use of orange peel essential oil in ant sprays. PBI’s breakthrough Ultra Shear Technology™ (UST™) platform, for creation of extremely low-droplet size nanoemulsions of oils in water, offers added value for a new generation of products with improved effectiveness and economics, allowing less active material to deliver higher effectiveness when applied or consumed. We are aggressively driving the creation of pioneering partnerships around UST in application sectors from pharmaceuticals to nutraceuticals to food/beverage and many more areas, as PBI’s core strategy for growth and profitability. We have singled out agrochemicals for a more aggressive forward integration into an applications sector for UST, in a bid to accelerate the cycle of education, trial, market demonstration, product differentiation, and uniquely advantaged growth. We are delighted to be sharing these insights into PBI’s expected accelerating growth trajectory and path to profitability with our loyal investor base.”

The asset acquisition is subject to certain conditions, including the completion of all due diligence and acquisition financing.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:
Richard T. Schumacher, President & CEO, (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing, (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman, (650) 703-8557 (T)

$POAI Fluorescent Imaging Agent May Allow for Better Cervical Cancer Detection

$NETE Report Suggests England Can Benefit More by Establishing Home EV Charging Infrastructure

$INM to Present at H.C. Wainwright Ophthalmology Virtual Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced its plans to participate at the upcoming H.C. Wainwright Ophthalmology Virtual Conference. According to the update, InMed’s CEO and President Eric. A. Adams and SVP of Pre-Clinical Research and Development Dr. Eric Hsu will present at the conference on Tuesday, Aug. 17, 2021. Adams and Dr. Hsu will provide an overview of the company’s ocular program, including INM-088, a topical eye drop formulation under development for the treatment of glaucoma. INM-088’s active pharmaceutical ingredient (“API”) is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye. The on-demand presentation will be available at 7:00 a.m. ET on Aug. 17, 2021, accessible from the HC Wainwrights events platform. An archived replay of the presentation will be available on InMed’s website immediately following the conference for 90 days.

To view the full press release, visit https://ibn.fm/1W2sS

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at http://ibn.fm/INM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$IDEX Biometrics ASA releases Interim Report for the First Half of 2021

Oslo, Norway – 12 August 2021 – IDEX Biometrics ASA (IDEX Biometrics or the Company), a leading provider of advanced fingerprint identification and authentication solutions for payment cards and adjacent applications, today released its financial results for the three and six months ended June 30, 2021.

The first half report, to be filed with Financial Supervisory Authority in Norway (Finanstilsynet),  and other materials are accessible on the Company’s website: www.idexbiometrics.com/investors/interim-results/ .

On 12 August, 2021, at 15:00 CET, Vince Graziani, Chief Executive Officer, will conduct a webcast presentation during which he will review results. The webcast presentation can be accessed through: https://channel.royalcast.com/landingpage/hegnarmedia/20210812_2/

Performance Review

For the second quarter ended June 30, 2021, IDEX Biometrics recorded revenue of $697 thousand, compared to $149 thousand for the second quarter of 2020, representing an increase of 368%. Sequentially, revenues increased 12% from first quarter 2021 revenue of $624 thousand.

Total operating expenses for the second quarter of 2021 were $8.1 million, compared to $6.3 million for the second quarter of 2020, representing an increase of 29%. Operating expenses were flat sequentially.

Net loss for the second quarter of 2021 totaled ($7.2 million), representing a loss per share of ($0.01), in contrast to ($6.4 million) for the second quarter of 2020, representing a loss per share of ($0.01), and ($7.5 million) for the first quarter of 2021, representing a loss per share of ($0.01).

The Company incurred an operating cash deficit of ($6.7 million) for the second quarter of 2021, versus ($5.7 million) for the second quarter of 2020 and ($6.9 million) for the first quarter of 2021. The Company’s cash balance totaled $19.3 million as of June 30, 2021, versus $25.9 million as of March 31, 2021.

Commercial and Market Updates

Second quarter 2021 events reflected continued progress toward large-scale smart card deployment with customers and issuers:

• The Company received its first significant production order for its TrustedBio solution from IDEMIA, supporting the launch of IDEMIA’s second-generation F.CODE card earlier in the quarter.
• Activities in Asia, notably China, are resulting in further expansion of the Company’s pipeline of opportunities for near-term revenue, with biometrically-enabled applications in payment cards, multi-use cards (e.g., payment cards also used for electronic ticketing), the rapidly evolving DCEP space, and access control.

The Company continues to enjoy sustained demand from its initial customer for a card-based access control solution for computer networks, addressing the vulnerabilities of password-based credentials with an easy-to-use, cost effective, and highly secure solution based on the Company’s technologies.

Commenting on recent events and performance, Vince Graziani, Chief Executive Officer, stated, “I am pleased to report the Company’s order backlog continued its promising expansion, and I am confident the long-awaited uptake in fingerprint-based card authentication is approaching.  In addition, recently announced commercial achievements and the strengthening of the Company’s leadership team are both important factors contributing to my confidence. Notably, IDEX Biometrics and Infineon Technologies AG, on July 15, jointly announced a new reference design for the highest performance smart card with fingerprint authentication. Based on Infineon’s latest secure element microprocessor, specifically optimized for integration of our TrustedBio ^TM solution, this reference design enables fingerprint-authenticated EMV payment card transactions that are three times faster than currently available solutions.“

Mr. Graziani continued, “Our partners recognize our innovative and highly-differentiated products address the challenges of high costs and unsatisfactory performance head on.  TrustedBio’s advantages allow for reduced component count, faster time to market, and lower card manufacturing complexity. TrustedBio integrates a large-area sensor and a powerful, yet small-footprint, ASIC into one device offering image capture, algorithmic processing, power harvesting and management, and encryption. No competitor comes close to providing the performance and economic benefits of TrustedBio.”

For further information contact:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 9180 0186

About IDEX Biometrics

IDEX Biometrics ASA (OSE: IDEX and NASDAQ: IDAF) is a leading provider of a leading provider of advanced fingerprint identification and authentication solutions for payment cards and adjacent applications, offering simple, secure and personal authentication for all.  We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions.  Our total addressable market represents a fast growing multi-billion-unit opportunity.

For more information, visit www.idexbiometrics.com and follow on Twitter @IDEXBiometrics

Trademark Statement

The wordmark ‘IDEX’, the trade name TrustedBio, and the IDEX logo are registered trademarks of IDEX Biometrics ASA. All other brands or product names are the property of their respective holders.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

$FNGR Schedules a Corporate Update Call for August 25 Against the Backdrop of Recent Positive Announcements

$FLGC Applauds Nasdaq in Promoting Diversity, Announces Strategic Board Appointment

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced acceleration of its transition plans to be compliant with the recently approved Nasdaq board diversity initiatives. As part of this transition, Flora has appointed Lead Scientific Advisor Dr. Annabelle Manalo-Morgan, PhD, to its board of directors, effective immediately. Approved by the SEC on August 6, 2021, Nasdaq’s board diversity rule is a disclosure standard designed to encourage a minimum board diversity objective for companies and provide stakeholders with consistent, comparable disclosures concerning a company’s current board composition. The Flora team shares these fundamental values regarding diversity and takes meaningful action to support social equality, promote inclusiveness and champion each individual’s unique mix of experiences and perspectives. Dr. Annabelle is a scientist, educator, author, mother of five, respected key opinion leader, and a philanthropist and entrepreneur focused on pharmaceutical innovation and clinical trial research in medical cannabis. “We are honored to welcome Dr. Annabelle to our board of directors. Her appointment will be critical to our commitment to cannabinoid research and our future success as we continue navigating complex international markets and building out our global distribution platform,” said Luis Merchan, president and CEO of Flora. “Further, I’d like to applaud the efforts of the Nasdaq exchange in promoting diversity in corporate America and the efforts from the Flora team to quickly develop and execute a strategy to position us as leaders in our industry, as we strive to advance our mission of improving lives around the world through cannabis.”

To view the full press release, visit https://ibn.fm/SL5U5

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at http://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$CYBN Notes Q1 Milestones for Subsidiary

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Consequently, the company announced that, in accordance with the agreement, Class B common shares will be issued to Adelia shareholders to satisfy the  $379,021.24 due to them on meeting of the relevant milestones. Those shares are exchangeable for common shares in the capital of Cybin, the announcement noted. Adelia aims to develop medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs. Adelia is focused on developing medicinal psychedelics that offer improved dosing efficacy and therapeutic indices to address unmet medical needs. The company is particularly intent on the development of treatment regimens consisting of proprietary psychedelic molecules and related clinical protocols.

To view the full press release, visit https://ibn.fm/DWLHC

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$BRSF Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector. This powerful technology can provide opportunities for motor rehabilitation from a number of conditions and even help patients who’ve lost the ability to speak. “Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the groundbreaking technology that aims to enable what was inconceivable until recently.”

To view the full article, visit: https://ibn.fm/oiwdT

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$ANPC Featured in Coverage of Investor Summit Group’s Q3 Virtual Event

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit the company’s website at www.anpacbio.com

To view IBN’s virtual coverage of Investor Summit Group’s Q3 Virtual Event, visit https://ibn.fm/2021InvestorSummitQ3

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at this month’s Investor Summit. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$TOBAF Improves Independence and Corporate Governance with Additions to its Board of Directors

LAS VEGAS and VANCOUVER, British Columbia, Aug. 11, 2021 — TAAT ™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT ™ ”) is pleased to announce that it has appointed Peter Nguyen and John Martin to its Board of Directors as independent directors, effective today. Mr. Nguyen and Mr. Martin have also been appointed as audit committee members of the Company. Following their appointments, the Company’s Board of Directors will consist of six directors, four of whom are independent directors as required by leading public stock exchanges. The Company’s audit committee members are all independent directors consisting of John Cumming, John Martin, and Peter Nguyen.

Peter Nguyen is a Chartered Professional Accountant and an alumnus of the University of British Columbia. Mr. Nguyen serves as an officer and director of several publicly traded companies in a variety of industries. Mr. Nguyen has more than 10 years of experience in various financial reporting and business strategy positions and has held several senior financial positions for public and private entities where he provides assurance, corporate financing, tax, and business advisory services.

John Martin has over 35 years of international business experience, mainly in capital markets and fund management. Mr. Martin held senior positions with Royal Bank of Canada and for 10 years was Head of Capital Markets at Bank of Tokyo Mitsubishi (Switzerland). In 2002, he established CMI Credit Market Investments Sarl., an advisory firm active in distressed debt.

The Company’s Board of Directors has been diligently working to institute updated regulatory and compliance procedures with a focus on establishing and maintaining Disclosure Controls and Procedures (“DC&P”), Internal Control over Financial Reporting (“ICFR”), and other corporate governance protocols in accordance with the regulations and standards of leading public stock exchanges. The Company previously announced its application to list its common shares on the Nasdaq Capital Market in a press release dated April 23, 2021.

TAAT™ Chief Executive Officer Setti Coscarella commented, “On behalf of the Company’s Board of Directors, we are pleased to welcome Mr. Nguyen and Mr. Martin to the team, who are each bringing to the table unique expertise in public companies. TAAT™ has made considerable strides in the past year, with public market presences in good standing in Canada, the United States, and Germany. Within just nine months of being publicly listed in Canada, TAAT™ ascended to the OTCQX® Best Market in the United States. Moreover, upon becoming a ‘post-revenue’ company at the end of 2020, TAAT™ was added to the CSE Composite Index® as well as its CSE25™ subset (the 25 largest firms in Composite by market capitalization). We look forward to working with Mr. Nguyen and Mr. Martin as we continue our initiatives to build market share in the USD $814 billion global tobacco industry.”

On behalf of the Board of Directors of the Company,

TAAT ™ GLOBAL ALTERNATIVES INC.

“Setti Coscarella”

Setti Coscarella, CEO and Director

For further information, please contact:

TAAT™ Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatusa.com

THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

About TAAT ™ Global Alternatives Inc.

The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ was launched first in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion ¹ global tobacco industry.

For more information, please visit http://taatglobal.com .

References

¹ British American Tobacco – The Global Market

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT™ in the tobacco industry, in addition to the following: Potential outcomes from the addition of two new members to the Company’s Board of Directors, potential outcomes relating to the planned introduction of regulatory and compliance procedures as detailed in the press release. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.

The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.

This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.

Statement Regarding Third-Party Investor Relations Firms

Disclosures relating to investor relations firms retained by TAAT™ Global Alternatives Inc. can be found under the Company’s profile on http://sedar.com .

$SRAX Launches Key Features to Promote Frictionless Communication on Sequire Platform

SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform. In an effort to bridge the gap between listed corporations and investors, the company recently introduced a number of key platform enhancements. “Sequire has recently released new features to help facilitate communication between its listed corporate subscribers and retail investor base, consisting of an automated email feature as well as an SMS function,” reads a recent article. “Sequire’s listed corporate base will have access to custom filters to assist them in structuring campaigns directed at specific investor categories, along with automation triggers, machine learning and other enhancements designed to promote frictionless communication between corporations and the millions of retail investors on their platform. ‘These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,’ said SRAX founder and CEO Christopher Miglino (https://ibn.fm/u0ITG).”

To view the full article, visit https://ibn.fm/3Gory

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$WTER Alkaline88(R) to Hit Shelves in 400+ United Pacific, Rocket-Branded Convenience Stores

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company, today announced that its Alkaline88(R) Deliciously Smooth(TM) water will soon be available in over 400 United Pacific stores throughout the Western United States. According to the update, the move is made possible through WTER’s partnership with Core-Mark, which will be distributing the product from its centers throughout the western region. “United Pacific is a great win for us. Alkaline88 will launch in late August or early September in over 400 United Pacific, Rocket-branded convenience stores. United Pacific is a market leader in California, Oregon, Washington, and Colorado,” said Ricky Wright, president and CEO of The Alkaline Water Company. “The c-store channel remains a focus for us in fiscal 2022. We expect to see a significant increase in volume and revenue from this relationship.”

To view the full press release, visit https://ibn.fm/NRmIE

About The Alkaline Water Company Inc.

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors with new flavors coming soon. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for the Alklaine88 and A88 Infused brands. To purchase Alkaline88 and A88 Flavor Infused products online, visit www.Alkaline88.com. To learn more about the company, visit www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$SGTM Positioned to Benefit from Expected 65% Lumber Price Rally

• U.S. government infrastructure plans, rising housing demand, seasonal trends pointing to potential 65% increase in lumber prices by end of 2021
• SGTM transforms storm waste into gardening mulch, playground surfacing material, specialty cypress lumber
• Clients include Circle K, The Kroger Company, 7-Eleven, Old Castle Lawn & Garden
• Company completed two-year audit, commenced FORM-10 process in preparation for NASDAQ uplist

Biden’s infrastructure plans, seasonal trends and an expected increase in housing demand are setting the stage for a potential 65% increase in the cost of lumber, according to experts (https://ibn.fm/K3vD5). Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is positioned to benefit from rising prices through the manufacture of specialty cypress lumber via the company’s sawmill operations.

Lumber prices may have taken a fall from their 2020 peak, but analysts are expecting a sharp rebound by the end of 2021. The nearly $1 trillion bipartisan infrastructure deal, combined with the continued rise of housing prices and seasonal trends, is setting the stage for a massive increase in the cost of lumber according to Joshua Mahony, a senior market analyst at the IG trading platform (https://ibn.fm/K3vD5).

“There is good reasoning behind the idea that the losses we are seeing over recent months could soon enough bring another major buying opportunity for the bulls to come back into dominance,” said Mahony. “That reversal historically results in a bullish reversal to regain lost ground and bring us back into a positive end to the year. This current pullback is in fact part of a seasonal trend that typically resolves in a dramatic recovery towards the end of the year.”

SGTM is poised to benefit from the lumber price rally by providing synergistic and environmentally beneficial solutions to tree and storm waste disposal that have historically created environmental burdens on disposal sites around the country. Rather than allow this natural waste to be directed to landfills, SGTM collects tree biomass and transforms it into playground surfacing material, specialty cypress lumber, and a variety of organic, next-generation mulch products that allow water and air to penetrate the soil and roots — a vital process that promotes plant health and growth.

After concluding a record-breaking year in 2020 with impressive financial results so far in 2021, SGTM continues its expansion plans through a strategy that focuses on organic growth, relationships with strategic partners, and expanded relationships with top global franchises that include Circle K, The Kroger Company, 7-Eleven and Old Castle Lawn & Garden. In addition to completing a two-year audit, the company commenced its FORM-10 process to become fully reporting with future plans to uplist to NASDAQ.

SGTM’s centralized operations are based in Jacksonville, Florida across 26 acres with ample room to expand. With over 40 years of next-level experience with mulch manufacturing and tree management, SGTM’s leadership is committed to sustainably growing the company through a multi-pronged strategy that puts stewardship of the environment at the core of its mission.

To learn more about Sustainable Green Team, please visit www.NationalArborCare.com and view the investor presentation at https://ibn.fm/GBgnK.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

$RWBYF Featured in Latest Episode of ‘Bell2Bell’ Podcast

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, was featured in the “Bell2Bell Podcast,” a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Red White & Bloom’s CEO and Executive Chair Brad Rogers joined the latest episode to discuss the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets. “Red White & Bloom (‘RWB’) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”

To view the full press release, visit https://ibn.fm/PUTJe

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$POAI Announces Adjournment of Special Meeting of Stockholders

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The reason for the adjournment was to solicit more votes on a key proposal. According to the announcement, the proposal in questions calls for approval of an amendment to the company’s certificate of incorporation to increase the number of authorized shares of company common stock to 200 million; the current number of authorized shares of common stock is 100 million. During the meeting, stockholders voted and approved several other proposals, including an amendment to the Amended and Restated 2012 Stock Incentive Plan, the issuance of additional shares of common stock of the company based on a previously approved equity line of credit arrangement; and the ratification of the appointment of Baker Tilly US LLP as POAI’s independent registered public accounting firm for the fiscal year ending December 31, 2021. Before the next scheduled meeting, POAI will solicit proxies from its stockholders. POAI is also encouraging all stockholders who have not yet voted to do so as soon as possible.

To view the full press release, visit https://ibn.fm/5iHcX

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood and irrigation fluid, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$PLTXF Bloombox UK Collaborates to Launch Campaign Celebrating Release of Disney’s Jungle Cruise

PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced that its wholly owned subsidiary Bloomboxclub Limited, a U.K.-based e-commerce platform that sells and delivers indoor plants, is collaborating with The Walt Disney Company (NYSE: DIS) in the U.K. The partners are teaming up for a campaign to promote Bloombox products and celebrate the release of Disney’s new film, Jungle Cruise, now showing in cinemas and on Disney+ with Premier Access (subscription and additional fee required). As part of the new co-branded campaign, Bloombox will promote the adventure-filled film through the launch of a new Amazonian plant collection, including Jungle Cruise inspired terrariums, a social media campaign and a “Hunt for the Healing Tree” treasure hunt on the Bloombox website. “Bloombox’s collaboration with Disney is truly a momentous opportunity to celebrate plants and their integral role and impact across the film industry,” said PlantX Founder Sean Dollinger. “We are beyond thrilled to have Disney’s support in sharing the Bloombox exotic plant collection with our community.”

To view the full press release, visit https://ibn.fm/vQv1n

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at https://Investor.PlantX.com.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$NEXCF CEO Featured in Proactive Investors Livestream Metaverse Discussion

Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (“AR”) for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events, has announced that CEO Evan Gappelberg will be participating in an upcoming virtual event. The special Proactive Investors Livestream will feature a discussion about the Metaverse and Nextech’s recent acquisition of spatial-based computing company ARWAY Ltd. ARWAY founder and CEO Baran Korkmaz will also be a guest speaker during the webinar. ARWAY offers a Unity-based platform that uses AI to scan and recognize surroundings for hyper-accurate, location-based 3D mapping. The company also offers users an Augmented Reality Software Kit (“SDK”) to frame the digital world in a few minutes. According to the announcement, the acquisition provides Nextech with a spatial mapping platform essential to building the Metaverse. The livestream event is scheduled for Aug. 11, 2021, and will start at 12:30 p.m. ET.

To register for the full webinar, visit https://ibn.fm/AvKiw

To view the full press release, visit https://ibn.fm/wW6Nf

About Nextech AR Solutions Corp.

Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$LEXX Releases Partial Results from Human Clinical Trial of DehydraTECH(TM)-Processed Cannabidiol for Hypertension

$FLGC 420 with CNW- Is it Worthwhile to Use CBD Beauty Products?

$IDEX Leveraging Strong Pillars to Shape Future of Energy-Driven Commercial Fleets

Ideanomics (NASDAQ: IDEX), a global company focused on the convergence of financial services and industries experiencing technological disruption, is leveraging an innovative business model to capitalize on growth opportunities. “With its three strong pillars of EV (vehicles, charging and energy), IDEX is shaping the future of energy-driven commercial fleets through its two divisions, Ideanomics Mobility and Ideanomics Capital,” reads a recent article. The piece goes on to discuss the company’s focus on innovation through its business operations. These include US Hybrid, which specializes in the design and manufacturing of zero emission powertrain components for electric, hybrid, and fuel cell medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty vehicles throughout the world. Secondly, WAVE “powers the largest electric mass transit bus fleet in the U.S, at the Antelope Valley Transportation Authority north of Los Angeles with its wireless inductive charging pads.” Further, the article discusses Solectrac. “Ideanomic’s acquisition of this California-based facility reflects the company’s visionary approach towards the electric tractor revolution. This is a pioneering move benefitting farmers and crops, as EV solutions are still unheard of in this segment, while also grabbing a growing slice of agricultural market revenue.”

To view the full article, visit https://ibn.fm/j3zSj

About Ideanomics Inc.

Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales-to-financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential growth industries. For more information, visit www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

$EXN EU Regulators Boost the Renewables Sector

$CBDHF To Report Second Quarter 2021 Earnings and Host Conference Call on August 16, 2021

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“ HempFusion ” or the “ Company ”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, announced today it will report its financial results for the second quarter ended June 30, 2021 at 8:00 a.m. (Eastern Time) on Monday, August 16, 2021 followed by an 8:30 a.m. (Eastern Time), conference call and webcast with a question-and-answer session.

To participate in the call, please dial 888-506-0062. For international callers, please dial 973-528-0011. Use Entry Code: 746381.

To join the webcast, please visit https://www.webcaster4.com/Webcast/Page/2710/42495

A replay will be available from the Investor Relations section of HempFusion’s website at HempFusion.com/corporate-information .

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

Follow HempFusion on Twitter , Facebook and Instagram and Probulin on Twitter , Facebook and Instagram .

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005224/en/

Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638

$BRSF Brain Fingerprints May Facilitate Neurological Disease Detection